[
    {
        "outcome_uid": "b14eac22",
        "clinical_question": "Should patients with RA on DMARDs who are NOT at target receive IA corticosteroids alone or add/switch DMARDs or IA corticosteroids and add/switch DMARD(s)?",
        "population": "Patients with RA on DMARDs who are not at target",
        "intervention": "IA steroids",
        "comparator": "add/Switch DMARD(s)",
        "outcome": "Disease activity (follow up: 3 months; assessed with: ACR 20)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "5c2f0c43"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of allocation concealment, lack of blinding, and selective reporting."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious indirectness. Study compared IA GCs + csDMARD to csDMARDs."
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting no effect and value suggesting harm. Very small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "IA corticosteroids alone": "25/25 (100.0%)",
                    "Add/Switch DMARD(s)": "21/25 (84.0%)"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "RR 1.19 (0.99 to 1.43)",
                    "Absolute Effect (95% CI)": "160 more per 1,000 (from 8 fewer to 361 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "c6748830",
        "clinical_question": "Should patients with RA on DMARDs who are NOT at target receive IA corticosteroids alone or add/switch DMARDs or IA corticosteroids and add/switch DMARD(s)?",
        "population": "Patients with RA on DMARDs who are not at target",
        "intervention": "IA steroids",
        "comparator": "add/Switch DMARD(s)",
        "outcome": "Disease activity (follow up: 3 months; assessed with: ACR 50)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "5c2f0c43"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of allocation concealment, lack of blinding, and selective reporting."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious indirectness. Study compared IA GCs + csDMARD to csDMARDs."
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious imprecision. Very small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "IA corticosteroids alone": "15/25 (60.0%)",
                    "Add/Switch DMARD(s)": "5/25 (20.0%)"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "RR 3.00 (1.29 to 7.00)",
                    "Absolute Effect (95% CI)": "400 more per 1,000 (from 58 more to 1,000 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "564a2b56",
        "clinical_question": "Should patients with RA on DMARDs who are NOT at target receive IA corticosteroids alone or add/switch DMARDs or IA corticosteroids and add/switch DMARD(s)?",
        "population": "Patients with RA on DMARDs who are not at target",
        "intervention": "IA steroids",
        "comparator": "add/Switch DMARD(s)",
        "outcome": "Disease activity (follow up: 3 months; assessed with: ACR 70)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "5c2f0c43"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of allocation concealment, lack of blinding, and selective reporting."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious indirectness. Study compared IA GCs + csDMARD to csDMARDs."
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Very small sample size and low number of events."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "IA corticosteroids alone": "9/25 (36.0%)",
                    "Add/Switch DMARD(s)": "0/25 (0.0%)"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "RR 19.00 (1.17 to 309.77)",
                    "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 0 fewer to 0 fewer)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "192d97ba",
        "clinical_question": "Should patients with RA on DMARDs who are NOT at target receive IA corticosteroids alone or add/switch DMARDs or IA corticosteroids and add/switch DMARD(s)?",
        "population": "Patients with RA on DMARDs who are not at target",
        "intervention": "IA steroids",
        "comparator": "add/Switch DMARD(s)",
        "outcome": "Disease activity (follow up: 3 months; assessed with: DAS28-ESR)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "5c2f0c43"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of allocation concealment, lack of blinding, and selective reporting."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious indirectness. Study compared IA GCs + csDMARD to csDMARDs."
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect. Very small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "IA corticosteroids alone": "25",
                    "Add/Switch DMARD(s)": "25"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 1.6 lower (2.21 lower to 0.99 lower)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "0b64669d",
        "clinical_question": "Should patients with RA on DMARDs who are NOT at target receive IA corticosteroids alone or add/switch DMARDs or IA corticosteroids and add/switch DMARD(s)?",
        "population": "Patients with RA on DMARDs who are not at target",
        "intervention": "IA steroids",
        "comparator": "add/Switch DMARD(s)",
        "outcome": "Disability (follow up: 3 months; assessed with: HAQ-DI)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "5c2f0c43"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of allocation concealment, lack of blinding, and selective reporting."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious indirectness. Study compared IA GCs + csDMARD to csDMARDs."
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect. Very small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "IA corticosteroids alone": "25",
                    "Add/Switch DMARD(s)": "25"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 0.24 lower (0.42 lower to 0.06 lower)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    }
]